Abstract: Compositions include polymer filaments compatible with fused filament fabrication, comprising: a thermoplastic polymer; and a bio-based additive admixed with the thermoplastic polymer in an effective amount to decrease total volatile organic compound (TVOC) emissions under additive manufacturing conditions, as determined by gas chromatography and measured relative to the thermoplastic polymer alone, by at least about 10% on a weight basis. Methods for forming a polymer filament compatible with fused filament fabrication may comprise: forming a melt blend comprising a thermoplastic polymer and a bio-based additive; and extruding the melt blend and cooling to form a polymer filament comprising the bio-based additive admixed with the thermoplastic polymer.

Abstract: A system and method for an electronic cruise control used to supplement electronic control units or vehicles for enhanced or additional cruise control integration. The electronic cruise control is designed to be updated easily by the end user or system to adjust the speed of a vehicle such as a motorcycle whereby the electronic cruise system sends a control signal to rotate an existing throttle to maintain the motorcycle's speed whereby the throttle grip position will always reference the speed of the motorcycle.

Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.

Abstract: Provided are embodiments for a computer-implemented method for interacting with a user by an automated response system supporting topic switching and information collection. The computer-implemented method includes receiving a plurality of utterances from the user by the automated response system, and analyzing the utterances to form a first topic thread and an information collection objective. The computer-implemented method also includes utilizing an information collection user interface to gather data to support the information collection objective, and providing responses to the user after the gathered data related to the first topic thread. Also provided are embodiments for a system and computer program product for implementing the techniques described herein.

Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to compounds of formulae I and H, or pharmaceutically acceptable salts or esters thereof. Further aspects of the invention relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably. Alzheimer's disease.

Abstract: Layers of build and support material on an intermediate transfer surface are exposed to a solvent using a solvent application station to make the build material tacky, without affecting the support material. Then, the intermediate transfer surface moves past a transfuse station (the transfuse station is positioned to receive the layers after exposure to the solvent) and a platen moves relative to the intermediate transfer surface to contact the platen to one of the layers on the intermediate transfer surface. The intermediate transfer surface transfers a layer of the build material and the support material to the platen each time the platen contacts the layers on the intermediate transfer surface at the transfuse station to successively form a freestanding stack of the layers of build and support material on the platen.

Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.

Abstract: Provided are embodiments for a computer-implemented method for interacting with a user by an automated response system supporting topic switching and information collection. The computer-implemented method includes receiving a plurality of utterances from the user by the automated response system, and analyzing the utterances to form a first topic thread and an information collection objective. The computer-implemented method also includes utilizing an information collection user interface to gather data to support the information collection objective, and providing responses to the user after the gathered data related to the first topic thread. Also provided are embodiments for a system and computer program product for implementing the techniques described herein.

Abstract: The present invention relates to compounds of formulae I and H, or pharmaceutically acceptable salts or esters thereof. Further aspects of the invention relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably. Alzheimer's disease.

Abstract: The present invention relates to compounds of formulae I and H, or pharmaceutically acceptable salts or esters thereof. Further aspects of the invention relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably, Alzheimer's disease.

Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to compounds of formulae I, or pharmaceutically acceptable salts or esters thereof, wherein: R1 is selected from H and CO—NR8R9, wherein R8 and R9 are each independently selected from H, alkyl, cycloalkyl and mono or bicyclic heterocycloalkyl, wherein said alkyl group is optionally substituted by one or more R12 groups, and said heterocycloalkyl is optionally substituted by R10 or R12; or R8 and R9 are linked, together with the nitrogen to which they are attached, to form a heterocycloalkyl group optionally containing one or more additional heteroatoms, and optionally substituted by one or more groups select from R10 and (CH2)mR12; R2 is selected from H and alkyl, wherein said alkyl group is optionally substituted by one or more R12 groups; R3 is selected from alkyl, cycloalkyl and heterocycloalkyl, each of which may be optionally substituted by halo, OH or alkoxy; Z1, Z2, Z3 and Z4 are all C; R4, R5, R6 and R7 are each independently selected from H, alkyl, CN, NO2, OH, alkoxy, N

Abstract: A method of coordinating and exercising the extremities of a person by the independent and/or simultaneous gestures of both the hands and feet. The method comprises the computer, four USB ports and four wired and/or wireless mice that correspond to the four-cursor exponential cognitive human-man-interface (HMI) exercise application The HMI application will instruct the person to begin tracing each of the four cursors on separate tracks in the pattern towards a desired target by the gestures of both the hands and the feet (extremities), which are appended to the mice. Displaying the performance data of each extremity including time, distance, and speed measures the competitiveness of both the hands and the feet against each other. The goal is for the left-hand, right-hand, left-foot and right foot to reach the target at the same time at the fastest speed possible.

Abstract: An object surface treatment system facilitates the treatment of articles of manufacture before they are printed. The system includes a chamber having walls and a lid configured to close the chamber, a flexible member mounted to the lid of the chamber, a vacuum source operatively connected to an interior volume of the chamber, and a plurality of actuators. A controller is configured to operate the actuators and vacuum source to move the applicator to apply a chemical to the flexible member, move the lid to close the chamber, produce a vacuum within the chamber and move a portion of the surface of the flexible member into engagement with a surface of an object within the chamber, cease operation of the vacuum source to enable the flexible member to return to a position adjacent the lid, and remove the lid from the chamber for removal of the object from the chamber.

Abstract: Layers of build and support material on an intermediate transfer surface are exposed to a solvent using a solvent application station to make the build material tacky, without affecting the support material. Then, the intermediate transfer surface moves past a transfuse station (the transfuse station is positioned to receive the layers after exposure to the solvent) and a platen moves relative to the intermediate transfer surface to contact the platen to one of the layers on the intermediate transfer surface. The intermediate transfer surface transfers a layer of the build material and the support material to the platen each time the platen contacts the layers on the intermediate transfer surface at the transfuse station to successively form a freestanding stack of the layers of build and support material on the platen.

Abstract: Layers of build and support material on an intermediate transfer surface are exposed to a solvent using a solvent application station to make the build material tacky, without affecting the support material. Then, the intermediate transfer surface moves past a transfuse station (the transfuse station is positioned to receive the layers after exposure to the solvent) and a platen moves relative to the intermediate transfer surface to contact the platen to one of the layers on the intermediate transfer surface. The intermediate transfer surface transfers a layer of the build material and the support material to the platen each time the platen contacts the layers on the intermediate transfer surface at the transfuse station to successively form a freestanding stack of the layers of build and support material on the platen.

Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.

Abstract: Systems and methods are provided for managing a print job archive. The system includes a plurality of databases that store print job properties, wherein at least one database is designated to record the print job properties as a function of a predetermined characteristic of the print job. The system also includes an interface that receives multiple print jobs, and a data distribution module coupled with the plurality of databases and the interface. For each of the multiple print jobs, the data distribution module categorizes the print job based on at least one predetermined characteristic, identifies a database among the plurality of databases that is designated for the print jobs as a function of the at least one predetermined characteristic, and stores the print jobs in the identified database as a function of the at least one predetermined characteristic.

Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.